docetaxel anhydrous has been researched along with nsc 83265 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (nsc 83265) | Trials (nsc 83265) | Recent Studies (post-2010) (nsc 83265) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 51 | 0 | 24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnetson, R; Doyle, B; Fleming, J; Kozielski, F; Leung, HY; Robson, CN; Singh, BL; Stockley, J; Wiltshire, C | 1 |
1 other study(ies) available for docetaxel anhydrous and nsc 83265
| Article | Year |
|---|---|
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cysteine; Docetaxel; Drug Screening Assays, Antitumor; Humans; Kinesins; Male; Propidium; Prostatic Neoplasms; Taxoids; Up-Regulation | 2010 |